Archives
Browse through our archives, either by category or month.
Categories
- Alzheimers (184)
- Cancer (320)
- Drug Development (371)
- M&A (448)
- Neurological Disorders (91)
- News Wire (1002)
- Pharma Industry (591)
Monthly Archives
- July 2010 (146)
- June 2010 (160)
- May 2010 (152)
- April 2010 (152)
- March 2010 (214)
- February 2010 (114)
- January 2010 (131)
- December 2009 (147)
- November 2009 (86)
- October 2009 (122)
- September 2009 (142)
- August 2009 (62)
- July 2009 (142)
- June 2009 (159)
- May 2009 (112)
- April 2009 (119)
- March 2009 (141)
- February 2009 (138)
- January 2009 (95)
- December 2008 (118)
- November 2008 (131)
- October 2008 (151)
- September 2008 (67)
The Last 30 Posts
- Sanofi-Aventis readies $18.7B bid for Genzyme - Posted on 30 July 2010 - Comments (0)
- Senator Slams FDA Advisory Committee’s Avastin Decision - Posted on 30 July 2010 - Comments (0)
- AZ’s blockbuster Brilinta wins landslide FDA panel vote - Posted on 30 July 2010 - Comments (0)
- Novartis gives away new kids’ drug to challenge J&J - Posted on 30 July 2010 - Comments (0)
- Astellas Negotiates $295M License Extension to Regeneron’s VelocImmune mAb Platform - Posted on 29 July 2010 - Comments (0)
- FDA Advisory Panel Gives Thumbs-Up to AstraZeneca’s Brilinta - Posted on 29 July 2010 - Comments (0)
- FDA considering changes to risky drug safeguards - Posted on 29 July 2010 - Comments (0)
- Why Novartis’s Triaminic Giveaway Reminds Us of the Tour de France - Posted on 29 July 2010 - Comments (0)
- Test designed to screen resistance to cancer drug - Posted on 29 July 2010 - Comments (0)
- Pfizer aims for 6 more months of Viagra - Posted on 29 July 2010 - Comments (0)
- U.S. courts aren’t kind to Sanofi on Zimulti, Lovenox - Posted on 29 July 2010 - Comments (0)
- Novo’s Victoza drains new scrips from rivals - Posted on 29 July 2010 - Comments (0)
- Is Sanofi determined to take over Genzyme? - Posted on 28 July 2010 - Comments (0)
- Expert: ‘Persistent Uncertainty’ About H1N1’s Next Moves - Posted on 28 July 2010 - Comments (0)
- How much is Genzyme worth? - Posted on 28 July 2010 - Comments (0)
- Study Finds Aggressive Treatment of Low-Risk Prostate Cancer - Posted on 28 July 2010 - Comments (0)
- AZ’s Brilinta garners favorable reviews from FDA staffers - Posted on 28 July 2010 - Comments (0)
- GSK tosses sales targets for U.S. reps - Posted on 28 July 2010 - Comments (0)
- FDA calls on IG to probe Avandia panel conflict - Posted on 27 July 2010 - Comments (0)
- Pharma seeks FDA clarity on risky drug safeguards - Posted on 27 July 2010 - Comments (0)
- GSK Apologizes Over Medical Journal Snafu - Posted on 27 July 2010 - Comments (0)
- Sanofi-Aventis Reportedly Makes a Play for Genzyme - Posted on 27 July 2010 - Comments (0)
- Only some epilepsy drugs may raise suicide risk - Posted on 27 July 2010 - Comments (0)
- Onyx will seek early approval on blockbuster cancer candidate - Posted on 27 July 2010 - Comments (0)
- Eisai builds defenses against generic Aricept - Posted on 27 July 2010 - Comments (0)
- FDA orders halt to enrollment in Avandia trial - Posted on 26 July 2010 - Comments (0)
- Sanofi-Aventis Sidles Up to Genzyme With ‘Informal Approach,’ WSJ Reports - Posted on 26 July 2010 - Comments (0)
- Eisai say FDA approves higher dose Aricept - Posted on 26 July 2010 - Comments (0)
- J&J plant report heightens QC questions - Posted on 26 July 2010 - Comments (0)
- EU advice on Avandia put off until September - Posted on 26 July 2010 - Comments (0)
- Sanofi-Aventis readies $18.7B bid for Genzyme
- Senator Slams FDA Advisory Committee’s Avastin Decision
- AZ’s blockbuster Brilinta wins landslide FDA panel vote
- Novartis gives away new kids’ drug to challenge J&J
- Astellas Negotiates $295M License Extension to Regeneron’s VelocImmune mAb Platform
- FDA Advisory Panel Gives Thumbs-Up to AstraZeneca’s Brilinta
- FDA considering changes to risky drug safeguards
- Why Novartis’s Triaminic Giveaway Reminds Us of the Tour de France
- Test designed to screen resistance to cancer drug
- Pfizer aims for 6 more months of Viagra
- U.S. courts aren’t kind to Sanofi on Zimulti, Lovenox
- Novo’s Victoza drains new scrips from rivals
- Is Sanofi determined to take over Genzyme?
- Expert: ‘Persistent Uncertainty’ About H1N1’s Next Moves
- How much is Genzyme worth?
- FDA requests additional data on Roche's Actemra
- New pathway is a common thread in age-related neurodegenerative diseases
- ‘Company X’: Who Was Wyeth’s Other Suitor?
- FDA advisory panel set to review new diabetes drugs
- Report: GlaxoSmithKline may cut 6000 jobs
- Johnson & Johnson discusses pipeline, growth strategies
- Brain Teasers
- Roche says raised dividend stays; declines comment on reported increased bid for Genentech
- New technology holds promise for predicting breast cancer recovery
- Novartis Changes Division Heads, Plans U.S. Job Cuts
- New Use for Erbitux Stalled by FDA’s Data Request
- Bristol-Myers Squibb announces plans to boost cash flow up to $1 billion
- Cash-Poor Biotech Firms Cut Research, Seek Aid
- Eli Lilly faces major challenges
- China Biotech in Review: Deals, Developments and Financials
- Pharma Goes To Market (4)
- Vimpat Approved in Europe (3)
- Lilly to Acquire ImClone Systems in $6.5 Billion Transaction (3)
- Hyperactive Neurons and Amyloid, Side by Side (2)
- FDA approves AstraZeneca’s SEROQUEL XR (2)
- Genentech and OSI Pharmaceuticals Announce Topline Results from Phase III Study (2)
- Dendreon Announces Interim Data from Phase 3 PROVENGE IMPACT Trial (2)
- Protein shown to play a key role in normal development of nervous system (2)
- Teva and Kowa Announce Strategic Partnership (1)
- Astellas and Maxygen Announce Global Development Agreement (1)
- Abraxis and ProMetic Enter License Agreements for Up to $295 M US For Four Biopharmaceuticals (1)
- China Biotech in Review: Deals, Developments and Financials (1)
- Maui company studies noni as cancer treatment (1)
- Lilly Breaks The Mold With Buy Of ImClone (1)
- Cancer Is a Preventable Disease of Our Western Lifestyle (1)